Cruz-Jentoft AJ, Sayer AA. Sarcopenia. The Lancet. 2019;393(10191):2636–46.

Article  Google Scholar 

Liu P, Hao Q, Hai S, Wang H, Cao L, Dong B. Sarcopenia as a predictor of all-cause mortality among community-dwelling older people: a systematic review and meta-analysis. Maturitas. 2017;103:16–22.

Article  PubMed  Google Scholar 

Yeung SS, Reijnierse EM, Pham VK, Trappenburg MC, Lim WK, Meskers CG, Maier AB. Sarcopenia and its association with falls and fractures in older adults: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019;10(3):485–500.

Article  PubMed  PubMed Central  Google Scholar 

Sayer AA, Cooper R, Arai H, Cawthon PM, Ntsama Essomba MJ, Fielding RA, et al. Sarcopenia. Nat Rev Dis Primers. 2024;10(1):68.

Article  PubMed  Google Scholar 

Hurst C, Robinson SM, Witham MD, Dodds RM, Granic A, Buckland C, et al. Resistance exercise as a treatment for sarcopenia: prescription and delivery. Age Ageing. 2022;51(2):afac003.

Article  PubMed  PubMed Central  Google Scholar 

Deane CS, Willis CR, Gallagher IJ, Brook MS, Gharahdaghi N, Wylie LJ, et al. Nicotinic acid improves mitochondrial function and associated transcriptional pathways in older inactive males. Transl Exercise Biomed. 2024;1(3–4):277–94.

Article  Google Scholar 

Migliavacca E, Tay SK, Patel HP, Sonntag T, Civiletto G, McFarlane C, et al. Mitochondrial oxidative capacity and NAD+ biosynthesis are reduced in human sarcopenia across ethnicities. Nat Commun. 2019;10(1):5808.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Membrez M, Migliavacca E, Christen S, Yaku K, Trieu J, Lee AK, et al. Trigonelline is an NAD+ precursor that improves muscle function during ageing and is reduced in human sarcopenia. Nat Metab. 2024;6(3):433–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Campelj D, Philp A. NAD+ Therapeutics and skeletal muscle adaptation to exercise in humans. Sports medicine (Auckland, NZ). 2022;52(Suppl 1):91–9.

Article  Google Scholar 

Connell NJ, Grevendonk L, Fealy CE, Moonen-Kornips E, Bruls YMH, Schrauwen-Hinderling VB, et al. NAD+-precursor supplementation with L-tryptophan, nicotinic acid, and nicotinamide does not affect mitochondrial function or skeletal muscle function in physically compromised older adults. J Nutr. 2021;151(10):2917–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barker FJ, Hart A, Sayer AA, Witham MD. Effects of nicotinamide adenine dinucleotide precursors on measures of physical performance and physical frailty: a systematic review. JCSM Clinical Reports. 2022;7(4):93–106.

Article  Google Scholar 

Igarashi M, Yamauchi T. Insight into the application of nicotinamide mononucleotide (NMN) to age-related disorders. J Cellular Mole. 2023;2(1):9–13.

Google Scholar 

Van De Weijer T, Phielix E, Bilet L, Williams EG, Ropelle ER, Bierwagen A, et al. Evidence for a direct effect of the NAD+ precursor acipimox on muscle mitochondrial function in humans. Diabetes. 2015;64(4):1193–201.

Article  PubMed  Google Scholar 

Connell NJ, Houtkooper RH, Schrauwen P. NAD+ metabolism as a target for metabolic health: have we found the silver bullet? Diabetologia. 2019;62(6):888–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Edlund A, Musatti L, Wennmalm Å. Acipimox stimulates skin blood flow by a cyclo-dxygenase-dependent mechanism. Eur J Clin Pharmacol. 1990;39:37–41.

Article  CAS  PubMed  Google Scholar 

McDonald C, Alderson C, Birkbeck MG, Brown L, Del Din S, Gorman GG, et al. A study protocol to investigate if acipimox improves muscle function and sarcopenia: an open-label, uncontrolled, before-and-after experimental medicine feasibility study in community-dwelling older adults. BMJ Open. 2024;14(2): e076518.

Article  PubMed  PubMed Central  Google Scholar 

Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.

Article  PubMed  Google Scholar 

Offord NJ, Clegg A, Turner G, Dodds RM, Sayer AA, Witham MD. Current practice in the diagnosis and management of sarcopenia and frailty–results from a UK-wide survey. J Frailty, Sarcopenia Falls. 2019;4(3):71.

Article  PubMed  Google Scholar 

Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–57.

Article  CAS  PubMed  Google Scholar 

Witham MD, Wason J, Dodds R, Sayer AA. Developing a composite outcome measure for frailty prevention trials – rationale, derivation and sample size comparison with other candidate measures. BMC Geriatrics. 2020;20(1):113.

Article  PubMed  PubMed Central  Google Scholar 

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.

Article  CAS  PubMed  Google Scholar 

Pfizer ltd. Summary of product characteristics olbetam capsules 250. Electronic Medicines compendium. 2021. https://www.medicines.org.uk/emc/product/1357/smpc. Accessed 11/03/2025.

Porteous WK, James AM, Sheard PW, Porteous CM, Packer MA, Hyslop SJ, et al. Bioenergetic consequences of accumulating the common 4977-bp mitochondrial DNA deletion. Eur J Biochem. 1998;257(1):192–201.

Article  CAS  PubMed  Google Scholar 

Old SL, Johnson MA. Methods of microphotometric assay of succinate-dehydrogenase and cytochrome-C oxidase activities for use on human skeletal-muscle. Histochem J. 1989;21(910):545–55.

Article  CAS  PubMed  Google Scholar 

Rocha MC, Grady JP, Grünewald A, Vincent A, Dobson PF, Taylor RW, et al. A novel immunofluorescent assay to investigate oxidative phosphorylation deficiency in mitochondrial myopathy: understanding mechanisms and improving diagnosis. Sci Rep-Uk. 2015;5(1):15037.

Article  CAS  Google Scholar 

Grady JP, Murphy JL, Blakely EL, Haller RG, Taylor RW, Turnbull DM, Tuppen HAL. Accurate measurement of mitochondrial DNA deletion level and copy number differences in human skeletal muscle. PLoS ONE. 2014;9(12): e114462.

Article  PubMed  PubMed Central  Google Scholar 

Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85-94.

Article  CAS  PubMed  Google Scholar 

Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, Sayer AA. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011;40(4):423–9.

Article  PubMed  Google Scholar 

Kirk C, Küderle A, Micó-Amigo ME, Bonci T, Paraschiv-Ionescu A, Ullrich M, et al. Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device. Sci Rep-Uk. 2024;14(1):1754.

Article  CAS  Google Scholar 

Micó-Amigo ME, Bonci T, Paraschiv-Ionescu A, Ullrich M, Kirk C, Soltani A, et al. Assessing real-world gait with digital technology? Validation, insights and recommendations from the Mobilise-D consortium. J NeuroEng Rehab. 2023;20(1):78.

Article  Google Scholar 

Hollingsworth KG, Newton JL, Taylor R, McDonald C, Palmer JM, Blamire AM, Jones DEJ. Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis. Clin Gastroenterol H. 2008;6(9):1041–8.

Article  Google Scholar 

Loughran T, Higgins DM, McCallum M, Coombs A, Straub V, Hollingsworth KG. Improving highly accelerated fat fraction measurements for clinical trials in muscular dystrophy: origin and quantitative effect of R2* changes. Radiology. 2015;275(2):570–8.

Article  PubMed  Google Scholar 

LACE Study Group, Achison M, Adamson S, Akpan A, Aspray T, Avenell A, et al. Effect of perindopril or leucine on physical performance in older people with sarcopenia: the LACE randomized controlled trial. J Cachexia, Sarcopenia Muscle. 2022;13(2):858–71.

Article  Google Scholar 

Witham MD, Achison M, Aspray TJ, Avenell A, Band MM, Donnan PT, et al. Recruitment strategies for sarcopenia trials: lessons from the LACE randomized controlled trial. JCSM rapid communications. 2021;4(2):93–102.

Article  Google Scholar